Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity
Authors' conclusion
This novel data show that clotting system abnormalities do not contribute to the intrinsic mechanisms underlying PCOS in this nonobese noninsulin resistant population of women with PCOS matched for age and BMI, and without evidence of underlying inflammation, but rather the clotting factor changes are an epiphenomenon coincident with obesity; therefore, increased coagulability is unlikely in these nonobese PCOS women.
Study context
- Population
- Weight and age-matched nonobese women with polycystic ovary syndrome (PCOS) and control womenmatched cohort
- Participants
- 29 vs 29
- Exposure
- Nonobese women with PCOS vs control women
- PCOSn = 29
- Controln = 29reference
- Outcome
- Plasma levels of a panel of nine clotting proteins known to differ in obese women with PCOS (SOMA-scan)
Methodological detailsweight and age-matched
- Weight and age-matched
Main finding
As reported in the abstract
Nine coagulation pathway proteins
- Seven pro-coagulation proteins (plasminogen activator inhibitor-1, fibrinogen, fibrinogen gamma chain, fibronectin, d-dimer, P-selectin, plasma kallikrein) did not differ between PCOS and controls
- Two anticoagulant proteins (vitamin K-dependent protein-S, heparin cofactor-II) did not differ between PCOS and controls
Observational data: associations, not effects.
Further findings
Free androgen index and AMH
- Higher free androgen index (FAI) and AMH in PCOS
Insulin resistance and C reactive protein
- Measures of insulin resistance and C reactive protein did not differ between PCOS and controls
Original publication
Coagulation factor dysregulation in polycystic ovary syndrome is an epiphenomenon of obesity. Clin Endocrinol (Oxf). Published 8 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →